Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00733993 · ClinicalTrials.gov registry record · Phase 1

Caffeine and Cocaine

A Phase 1 study of Cocaine Dependence, sponsored by Virginia Commonwealth University.

Completed
Registry status
Phase 1
Development phase
23
Enrollment target
1
Study location

NCT00733993: Completed Phase 1 study of Cocaine Dependence, sponsored by Virginia Commonwealth University.

NCT00733993 is a Phase 1 study of Cocaine Dependence that has completed, run by Virginia Commonwealth University. The registered enrollment target is 23 participants, below the 298-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00733993, a Phase 1 study of Cocaine Dependence, has completed, sponsored by Virginia Commonwealth University.

COMPLETED
Registry status
Phase 1
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

This study is being done to find out if medicines that affect a neurotransmitter (chemical messenger) in the brain called adenosine improve behavioral problems that are related to drug abuse. Another purpose of the study is to find out how genes related to adenosine change how people respond to these medicines. More information about how these medicines change behaviors may be helpful to come up with new treatments for drug abuse.

Primary Outcome

Visual Analog Scale Rating. Scores range from 0 to 100 with higher scores meaning greater intensity of response being rated.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Amphetamine
  • DRUG Caffeine 150 MG
  • DRUG Caffeine 300 MG

Study Locations (1)

Texas

  • The University of Texas Health Science Center, Houston - Houston

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2008-04
Est. Completion 2011-10
Phase Phase 1
Virginia Commonwealth University

558 total trials

What the finished NCT00733993 record still lists

NCT00733993 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 298-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Cocaine Dependence appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT00733993 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00733993 about?

NCT00733993 is a clinical study titled "Caffeine and Cocaine". This study is being done to find out if medicines that affect a neurotransmitter (chemical messenger) in the brain called adenosine improve behavioral problems that are related to drug abuse. Another purpose of the study is to find out how genes related to adenosine change how people respond to thes...

What is the current status of trial NCT00733993?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2008-04. Estimated completion is 2011-10.

What conditions does trial NCT00733993 study?

This clinical trial studies the following conditions: Cocaine Dependence.

What interventions are being tested in trial NCT00733993?

The interventions under investigation include: Placebo (DRUG), Amphetamine (DRUG), Caffeine 150 MG (DRUG), Caffeine 300 MG (DRUG).

Who is sponsoring clinical trial NCT00733993?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00733993 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cocaine Dependence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00733993's enrollment target sits among peer trials

23 35th of 38 higher than 4 of 38 other Cocaine Dependence trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cocaine Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00733993, the US trial registry maintained by the National Library of Medicine. NCT00733993 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.